Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone
暂无分享,去创建一个
C. Plaisant | J. Ciezki | C. Reddy | C. Mullins | B. Seal | A. Hussain | Y. Kwok | A. Valderrama | E. Onukwugha | C. Yong | Candice Yong
[1] Nikki M. Carroll,et al. Validating Billing/Encounter Codes as Indicators of Lung, Colorectal, Breast, and Prostate Cancer Recurrence Using 2 Large Contemporary Cohorts , 2014, Medical care.
[2] Ronald C. Chen,et al. Considerations for observational research using large data sets in radiation oncology. , 2014, International journal of radiation oncology, biology, physics.
[3] C. Mullins,et al. Skeletal-related events and mortality among older men with advanced prostate cancer. , 2014, Journal of geriatric oncology.
[4] J. Debus,et al. Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group , 2014, European Journal of Medical Research.
[5] C. Mullins,et al. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer , 2014, Current opinion in oncology.
[6] Eberechukwu Onukwugha,et al. Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.
[7] C. Mullins,et al. The Economic Burden of Skeletal-Related Events Among Elderly Men with Metastatic Prostate Cancer , 2014, PharmacoEconomics.
[8] Ben Shneiderman,et al. Temporal Event Sequence Simplification , 2013, IEEE Transactions on Visualization and Computer Graphics.
[9] Eberechukwu Onukwugha,et al. Variation in the Length of Radiation Therapy Among Men Diagnosed With Incident Metastatic Prostate Cancer , 2013 .
[10] F. Saad,et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. , 2012, European journal of cancer.
[11] M L Kilgore,et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.
[12] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[13] Xue Song,et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. , 2010, Journal of managed care pharmacy : JMCP.
[14] Henrik Toft Sørensen,et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.
[15] A. D'Amico,et al. NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[16] David J Harrison,et al. The cost of treating skeletal-related events in patients with prostate cancer. , 2008, The American journal of managed care.
[17] Anthony D'Amico,et al. Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[18] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[19] K. Weinfurt,et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] F. Saad,et al. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. , 2004, European urology.
[21] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[22] J. Coresh,et al. Adjusting survival curves for confounders: a review and a new method. , 1996, American journal of epidemiology.